Capital Advisors Ltd’s Vanda Pharmaceuticals VNDA Stock Holding History

Capital Advisors Ltd’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31K	Hold	5,000	–	–	﹤0.01%	595
2026 Q1	$35K	Hold	5,000	–	–	﹤0.01%	572
2025 Q4	$44K	Hold	5,000	–	–	0.01%	508
2025 Q3	$25K	Hold	5,000	–	–	﹤0.01%	609
2025 Q2	$24K	Sell	5,000 -234	-4%	-$1.02K	﹤0.01%	600
2025 Q1	$24K	Hold	5,234	–	–	﹤0.01%	588
2024 Q4	$25K	Hold	5,234	–	–	﹤0.01%	581
2024 Q3	$25K	Hold	5,234	–	–	﹤0.01%	579
2024 Q2	$30K	Buy	5,234 +234	+5%	+$1.21K	﹤0.01%	535
2024 Q1	$21K	Hold	5,000	–	–	﹤0.01%	582
2023 Q4	$21K	Sell	5,000 -94	-2%	-$379	﹤0.01%	560
2023 Q3	$22K	Buy	5,094 +94	+2%	+$522	﹤0.01%	540
2023 Q2	$33K	Hold	5,000	–	–	﹤0.01%	487
2023 Q1	$34K	Hold	5,000	–	–	0.01%	410
2022 Q4	$37K	Buy	+5,000	New	+$48.7K	0.01%	404

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Advisors Ltd's VNDA Position: Q2 2026 in Review

Capital Advisors Ltd held its Vanda Pharmaceuticals (VNDA) position steady in Q2 2026 at 5,000 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #595.

Capital Advisors Ltd first reported a position in VNDA in Q4 2022 and has held it in 15 quarters since. The position peaked at $44K in Q4 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Capital Advisors Ltd held 5,000 shares of Vanda Pharmaceuticals worth $31K as of Q2 2026.
Capital Advisors Ltd left its Vanda Pharmaceuticals share count unchanged in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #595 holding.
Capital Advisors Ltd first reported a position in Vanda Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Capital Advisors Ltd's Vanda Pharmaceuticals position peaked at $44K in Q4 2025.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.